‘Regular screening can reduce risk of cervical cancer among women'
1
2
3
Varanasi: An awareness programme was organised by Sathiya Kendra of the Institute of Medical Sciences (IMS), Banaras Hindu University (BHU), in joint collaboration with Mamta Health Institute for Mother and Child, New Delhi, and National Health Mission, UP govt, at the Government Postgraduate Ayurvedic College and Hospital on Monday.
The programme focused on critical topics of
HPV vaccine
, cervical cancer, and the importance of
cervical cancer screening
. The event featured Prof Sangeeta Rai, head of the department of Obstetrics and Gynaecology at IMS, BHU, as the resource person.
Prof Rai said that cervical cancer is recognised as the second leading cause of cancer-related deaths among women globally. She shared poignant stories of patients currently battling this devastating disease, which served to highlight the urgent need for increased awareness and proactive health measures.
She emphasised that regular screening can significantly reduce the incidence and mortality associated with cervical cancer. The programme's slogan, "Do Teeke Zindagi Ke," encapsulated the dual focus on vaccination and screening as essential components of
women's health
care.
The initiative aimed not only to educate women but also to engage young men in discussions about cervical cancer, recognising that awareness is a collective responsibility. By promoting education among youth, the programme sought to foster a supportive community that encourages informed health choices and proactive measures against cervical cancer.
Speaking on the occasion, college principal Prof Neelam Gupta, expressed her gratitude to Prof Rai for her invaluable insights and to all participants, including medical officers, teachers, staff, and students, for their active engagement in raising awareness about cervical cancer.
An interactive question-and-answer session allowed audience members to seek clarification and share their thoughts, further enriching the discussion. This collaborative effort marked a significant step toward empowering individuals with knowledge and resources to effectively combat cervical cancer in their communities.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
3 hours ago
- Time of India
New genetic markers offer hope for early detection of gallbladder cancer
Varanasi: Research scholars from Banaras Hindu University, Dr Ruhi Dixit, Dr Manoj Pandey and Dr Vijay Kumar Shukla, achieved breakthrough in gallbladder cancer research by identifying novel genetic biomarkers that could transform early detection and targeted treatment of this deadly disease. Using advanced Clariom D Microarray technology , the team analysed gene expression profiles from gallbladder cancer, cholelithiasis (gallstones) and healthy tissues. Dr Dixit said it was first time in India, a three-way comparative transcriptomic analysis revealed 10 key genes potential drivers of cancer growth. Most of these genes are involved in DNA repair so their dysfunction promotes growth of cancer. The study suggests that, regardless of carcinogenic trigger, genetic pathways primarily involve DNA repair mechanisms , making treatment challenging. Building on the team's prior transcriptomic study, these findings clarify pathways in carcinogenesis and differential gene expression. Additionally, five genes were common across all three groups, indicating their potential as markers of early transformation before cancer is full-fledged. The study identified 3,898 genes, of which 2,575 were upregulated and 1,323 were downregulated. Mismatch repair pathway, nucleotide excision repair, and homologous recombination were the main pathways were found to be involved in carcinogenesis. He said gallbladder cancer was among most common cancers in Gangetic belt, often diagnosed late with poor prognosis and a 5-year survival rate of 10-20 per cent. Despite 25 years research at BHU to identify its elusive causes, the study marks a significant advance. It is the first in India to compare genetic changes across cancer, gallstone and healthy tissues simultaneously. The newly identified genes could serve as biomarkers for early detection and personalised treatment, paving way for improved diagnosis, prognosis and therapy for gallbladder cancer.
News18
a day ago
- News18
India Bets On Jan Aushadhi Kendras For HPV Vaccine To Prevent Cervical Cancer, Adds 116 New Drugs
Last Updated: The list also includes medicines for heart diseases, diabetes, epilepsy, apart from various other types of cancers The government's plan a roll out a nationwide HPV vaccination drive for girls to prevent cervical cancer remains stalled due to insufficient vaccine stock. To tide over the problem, the Narendra Modi government's flagship affordable generic drugs scheme, Jan Aushadhi, has now decided to include the HPV or Human Papillomavirus among 116 new medicines being added to its portfolio. The final list of medicines, accessed by News18, lists the recombinant HPV quadrivalent vaccine, which is effective against diseases caused by HPV types 6, 11, 16, and 18. '…used for the prevention of HPV-associated cancers, such as cervical, vaginal, vulvar, and anal cancer", mentions the document in the category of usage of the drug. The vaccine is expected to be available at subsidised rates through Jan Aushadhi outlets. The objective of the planned offering is to offer timely access, even as the national rollout remains uncertain. 'While the meeting to discuss the status of the roll-out of the nationwide HPV vaccination campaign for girls (aged 9 to 14 years) is expected to take place during the last week of June, there is no update from the Serum Institute of India (SII) on the requested quantity of vaccine doses. Without them, we cannot decide timelines or go ahead," a senior government official told News18. Meanwhile, the Union government is trying to expand access to HPV vaccines via Prime Minister Narendra Modi's flagship Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP). 'The scheme has just rolled out the tender for marketing the HPV vaccine as part of the initiative to add 116 more medicines to its existing bouquet of over 2,100 drugs and 315 surgical and medical devices," another senior government official said, adding that the price of the vaccine available at Jan Aushadhi retail outlets may not be steeply discounted. However, it remains unclear how the tendering procedure will work as in India, only the Serum Institute of India is currently the licensed manufacturer of the HPV vaccine. For the private market in India, the HPV vaccine from SII — Cervavac — typically costs Rs 4,000 per dose. Other Medicines on the List The Jan Aushadhi scheme offers generic drugs priced at 50–90 per cent lower than their branded counterparts in the market. The new list of medicines will be available at 16,500 Jan Aushadhi Kendras across India by September. 'It takes three to six months to complete the procurement procedure and bring medicines onto the retail shelf. The list was finalised in March, and now the tendering process is underway," the second official said. A significant portion of the medicines being added are for the treatment of heart disease and diabetes — two of India's most pressing health challenges. While India is often called the 'Diabetes Capital of the World,' with over 74 million adults affected, it also accounts for approximately 60 per cent of the world's heart disease burden. The list also includes several cancer drugs, including Ibrutinib, used in the treatment of blood cancer and costing between Rs 7,000 and Rs 9,500, which severely hurts the pocket of middle and lower-income class patients and families. Also, the list includes Abiraterone Acetate, a drug used in the treatment of prostate cancer, blood cancer, Hodgkin's disease, and also prescribed in some cases of sickle cell anaemia. A bottle of 60 tablets of the drug costs around Rs 35,000. With inclusion under the scheme, the prices of these drugs—in their generic version—are expected to fall by at least 50 per cent. Several other drugs for therapeutic categories such as the central nervous system, epilepsy and seizures, chronic obstructive pulmonary disease (COPD), anti-allergy and bone deficiencies are also part of the list. In March, Union health minister JP Nadda said the scheme is helping over 10 lakh people access affordable medicines, leading to cumulative savings of Rs 30,000 crore. While the scheme has been helping those, who cannot afford branded medicines, if it manages to offer quality cancer drugs and the HPV vaccine at discounted prices, it could set a significant benchmark for public health affordability and access. First Published:
India Today
3 days ago
- India Today
Know the truth: Common myths about cervical cancer explained
According to Globocon 2020, cervical cancer is the 4th most common cancer amongst women globally. India alone accounts for one-quarter of the global burden, with an estimated 1,23,907 new cases and 77,348 deaths Today spoke with Dr Pratima Raj, Associate Consultant – Gynaecological Oncology, Manipal Hospital Old Airport gain insights on the most common misconceptions surrounding cervical cancer and why awareness is key to early detection and considerable awareness campaigns and media attention on cervical cancer and HPV vaccination, the topic remains riddled with misinformation. Myths persist around screening, vaccines, and HPV itself, often preventing timely intervention. With the right information, however, cervical cancer is largely preventable and HPV ONLY AFFECTS PROMISCUOUS WOMEN Fact: HPV can affect any sexually active woman. Even one sexual partner is enough to contract HPV. Studies reveal that over 80 percent of women will acquire HPV by age HAVING HPV MEANS YOU'LL GET CERVICAL CANCERFact: While HPV is common, most infections resolve on their own. Only persistent high-risk strains can lead to cancerous changes. Regular screening helps detect these HPV INFECTIONS HAVE SYMPTOMSFact: Most HPV infections are asymptomatic. High-risk strains often go unnoticed unless caught through Pap smears or HPV symptoms of cervical cancer (if present) include abnormal discharge, irregular or heavy bleeding, post-coital bleeding, and pelvic or abdominal SCREENING IS THE ONLY PREVENTIVE MEASUREadvertisementFact: In addition to Pap tests and HPV testing, lifestyle factors play a role. Avoiding smoking, delaying sexual activity, and limiting partners can reduce risk. Other risk factors include chlamydia or HIV infections and weakened VACCINATED WOMEN DON'T NEED PAP TESTSFact: The HPV vaccine doesn't protect against all cancer-causing strains. Even vaccinated women should continue regular Pap and HPV PAP TESTS ARE NEEDED ANNUALLYFact: Current guidelines recommend:Ages 21–29: Pap test every 3 yearsAges 30–65: Pap + HPV co-test every 5 years65 and older: screening may stop if past tests were normalMYTH: HPV CLEARS ON ITS OWNFact: While some infections resolve naturally, others persist and can lead to genital warts or monitoring is CERVICAL CANCER ENDS FERTILITYFact: Fertility-preserving treatments are now available for early-stage cases.A hysterectomy is not always CERVICAL CANCER IS HEREDITARYFact: Cervical cancer is caused by HPV, not inherited like breast or ovarian and screening remain the best ONLY WOMEN WITH MULTIPLE PARTNERS ARE AT RISKFact: Even one sexual encounter can expose someone to is a sexually transmitted infection, not a moral LONG GAPS IN SEXUAL ACTIVITY ELIMINATE RISKadvertisementFact: Cervical cancer can develop long after infection, regardless of recent sexual PAP TESTS DETECT OVARIAN OR UTERINE CANCERFact: Cervical screening only checks the does not detect cancers of the uterus, ovaries, or fallopian HPV VACCINES ARE ONLY FOR TEENAGERSFact: The vaccine is most effective before sexual activity, but still beneficial for those already sexually ONLY WOMEN SHOULD WORRY ABOUT HPVFact: All genders are vulnerable to is recommended for ages 9– CONDOMS FULLY PREVENT HPVFact: Condoms reduce but don't eliminate the risk due to skin-to-skin CERVICAL CANCER IS ALWAYS FATALFact: When detected early, treatment is highly effective, and survival rates are OLDER WOMEN ARE NOT AT RISK OF HPVFact: HPV can affect anyone, regardless of THERE'S NO CURE FOR CERVICAL CANCERSurgery, chemotherapy, and radiation therapy can be curative, especially in early stages. Cervical cancer is one of the few cancers that is largely preventable and highly treatable when detected vaccination, regular screening, and healthy lifestyle choices, women (and all who are at risk) can dramatically reduce their chances of developing this disease. Armed with facts rather than fears, every woman can take charge of her reproductive health and help ensure that cervical cancer becomes a chapter of the past, not the Reel
